- Question from Andra: Apart from TDM1, Xeloda, and Tykerb (none of these worked for my wife), are there any significant advances in the treatment of HER2-positive stage IV metastatic breast cancer?
- Answers - Eric Winer, M.D. Just for background, TDM1 is what is called an antibody drug conjugate. What that means is that it is Herceptin that is chemically linked to a small amount of the chemotherapy drug. It is a treatment that has been investigated for HER2-positive estrogen-receptor-positive disease, and for many but not all women it can be very effective. There are a number of new treatments for estrogen-receptor-positive HER2-positive disease but they are only in clinical trials. These drugs include pertuzumab, neratinib, and a host of other agents.
The Ask-the-Expert Online Conference called Updates From the 2010 San Antonio Breast Cancer Symposium featured Eric Winer, M.D. and Marisa Weiss, M.D. answering your questions about the latest updates on breast cancer risk, screening, and treatment in early and metastatic breast cancer.
Editor's Note: This conference took place in December 2010.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.